Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell F Brin

Showing results (11-20 of 95) with videos related to

Pageof 10
Sort By:
Scientific Reports|February 28, 2023
Modulation of amygdala activity for emotional faces due to botulinum toxin type A injections that prevent frowningShauna Stark, Craig Stark, Brian Wong, et al.
Medicine|July 27, 2023
Botulinum neurotoxins: Future innovationsAmy Brideau-Andersen, J Oliver Dolly, Mitchell F Brin
The Laryngoscope|February 4, 2015
Negative dystonia of the palate: a novel entity and diagnostic consideration in hypernasal speechCatherine F Sinclair, Kristina Simonyan, Mitchell F Brin, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|August 28, 2024
Versatility of OnabotulinumtoxinA in Aesthetic MedicineMitchell F Brin, John Maltman, Mary Ann Chapman, et al.
The Annals of Otology, Rhinology, and Laryngology|July 2, 2003
Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve sectionLucian Sulica, Andrew Blitzer, Mitchell F Brin, et al.
Archives of Physical Medicine and Rehabilitation|May 30, 2006
Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticityCatherine C Turkel, Beta Bowen, Jingyu Liu, et al.
Disease-A-Month : DM|August 27, 2002
Botulinum toxin type A (BOTOX) for treatment of migraineWilliam J Binder, Mitchell F Brin, Andrew Blitzer, et al.
Neuroscience|April 9, 2017
Botulinum neurotoxin type A-cleaved SNAP25 is confined to primary motor neurons and localized on the plasma membrane following intramuscular toxin injectionBrian B Cai, Joseph Francis, Mitchell F Brin, et al.
Medicine|July 27, 2023
Treatment of glabellar lines with Botox (onabotulinumtoxinA): Development, insights, and impactJean Carruthers, Alastair Carruthers, Andrew Blitzer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 12, 2008
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assayMitchell F Brin, Cynthia L Comella, Joseph Jankovic, et al.
Pageof 10

Showing results (11-20 of 95) with videos related to

Sort By:
Pageof 10
Scientific Reports|February 28, 2023
Modulation of amygdala activity for emotional faces due to botulinum toxin type A injections that prevent frowningShauna Stark, Craig Stark, Brian Wong, et al.
Medicine|July 27, 2023
Botulinum neurotoxins: Future innovationsAmy Brideau-Andersen, J Oliver Dolly, Mitchell F Brin
The Laryngoscope|February 4, 2015
Negative dystonia of the palate: a novel entity and diagnostic consideration in hypernasal speechCatherine F Sinclair, Kristina Simonyan, Mitchell F Brin, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|August 28, 2024
Versatility of OnabotulinumtoxinA in Aesthetic MedicineMitchell F Brin, John Maltman, Mary Ann Chapman, et al.
The Annals of Otology, Rhinology, and Laryngology|July 2, 2003
Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve sectionLucian Sulica, Andrew Blitzer, Mitchell F Brin, et al.
Archives of Physical Medicine and Rehabilitation|May 30, 2006
Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticityCatherine C Turkel, Beta Bowen, Jingyu Liu, et al.
Disease-A-Month : DM|August 27, 2002
Botulinum toxin type A (BOTOX) for treatment of migraineWilliam J Binder, Mitchell F Brin, Andrew Blitzer, et al.
Neuroscience|April 9, 2017
Botulinum neurotoxin type A-cleaved SNAP25 is confined to primary motor neurons and localized on the plasma membrane following intramuscular toxin injectionBrian B Cai, Joseph Francis, Mitchell F Brin, et al.
Medicine|July 27, 2023
Treatment of glabellar lines with Botox (onabotulinumtoxinA): Development, insights, and impactJean Carruthers, Alastair Carruthers, Andrew Blitzer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 12, 2008
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assayMitchell F Brin, Cynthia L Comella, Joseph Jankovic, et al.
Pageof 10